Vitaspring Biomedical annual stock-based compensation
2021
2022
2023
2024
2025
2026
Vitaspring Biomedical Stock-Based Compensation Growth & History (VSBC)
Vitaspring Biomedical's stock-based compensation was $0 for fiscal 2026.
View full Vitaspring Biomedical company overviewVitaspring Biomedical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-01-31 | $0 | −$109,911 | — |
| 2025 | 2025-01-31 | $109,911 | −$54,954 | −33.33% |
| 2024 | 2024-01-31 | $164,865 | −$25,500 | −13.40% |
| 2023 | 2023-01-31 | $190,365 | $23,192 | +13.87% |
| 2022 | 2022-01-31 | $167,173 | −$267,045 | −61.50% |
| 2021 | 2021-01-31 | $434,218 | — | — |
Vitaspring Biomedical quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-01-31 | $0 | $0 | — |
| Q3 2026 | 2025-10-31 | $0 | −$27,478 | — |
| Q2 2026 | 2025-07-31 | $0 | −$41,216 | — |
| Q1 2026 | 2025-04-30 | $0 | −$41,217 | — |
| Q4 2025 | 2025-01-31 | $0 | −$41,217 | — |
| Q3 2025 | 2024-10-31 | $27,478 | −$13,738 | −33.33% |
| Q2 2025 | 2024-07-31 | $41,216 | $0 | 0.00% |
| Q1 2025 | 2024-04-30 | $41,217 | $1 | +0.00% |
| Q4 2024 | 2024-01-31 | $41,217 | −$3,112 | −7.02% |
| Q3 2024 | 2023-10-31 | $41,216 | $4,707 | +12.89% |
| Q2 2024 | 2023-07-31 | $41,216 | −$31,802 | −43.55% |
| Q1 2024 | 2023-04-30 | $41,216 | $4,707 | +12.89% |
| Q4 2023 | 2023-01-31 | $44,329 | $306 | +0.70% |
| Q3 2023 | 2022-10-31 | $36,509 | −$7,514 | −17.07% |
| Q2 2023 | 2022-07-31 | $73,018 | $28,995 | +65.86% |
| Q1 2023 | 2022-04-30 | $36,509 | $1,405 | +4.00% |
| Q4 2022 | 2022-01-31 | $44,023 | — | — |
| Q3 2022 | 2021-10-31 | $44,023 | — | — |
| Q2 2022 | 2021-07-31 | $44,023 | — | — |
| Q1 2022 | 2021-04-30 | $35,104 | — | — |
Vitaspring Biomedical stock-based compensation trends
Over the last five fiscal years, Vitaspring Biomedical's stock-based compensation decreased from $434,218 to $0, a change of −$434,218. The latest reported quarter, Q4 2026, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vitaspring Biomedical source filings ↗